Graft Versus Host Disease Pipeline Therapeutics Assessment Report 2024 (Updated)

DelveInsight's, "Graft versus host disease Pipeline Insight 2024" report provides comprehensive insights about 60+ GvHD companies and 65+ pipeline drugs in Graft versus host disease (GVHD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Graft Versus Host Disease Pipeline Report
• In November 2024:- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.- A Randomized, Open Label, Positive Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of the Selected Regimen of Rovadicitinib in Moderate to Severe Chronic Graft-versus-host Disease in Third Line and Beyond. The aim of this study is to demonstrate that in subjects with moderate to severe chronic graft-versus-host disease in the third line and beyond, the use of rosuvastatin compared to the protocol chosen by the researchers can significantly improve the objective response rate of subjects at week 24.
• In November 2024:- Incyte Corporation- A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease. This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in participants with cGVHD.
• DelveInsight's Graft versus host disease pipeline report depicts a robust space with 60+ active players working to develop 65+ pipeline therapies for Graft versus host disease treatment.
• The leading companies working in the Graft versus host disease Market include AltruBio, Syndax Pharmaceutical, MaaT Pharma, Medac, CSL Behring, Takeda, Oncoimmue, ElsaLys Biotech, Xenikos, Incyte Corporation, Jazz Pharmaceutials, Kadmon Corporation, Regimmune Corporation, Medsenic, AstraZeneca, Biogen, Pfizer, Equillium, GlaxoSmithKline, Amgen, CTI BioPharma, Bristol-Myers Squibb, Synthetic Biologics, Evive Biotech, Orca Bio, Novartis, Roche, Millennium, and others.
• Promising Graft versus host disease Pipeline Therapies in the various stages of development include Ibrutinib, Prednisone, ruxolitinib, Axatilimab, GDC-8264, Ruxolitinib, Defibrotide, and others.

Request a sample and discover the recent advances in Graft Versus Host Disease @ Graft Versus Host Disease Pipeline Outlook Report- https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Graft Versus Host Disease Overview
Graft-versus-host disease (GvHD) is a systemic disorder that occurs when the graft's immune cells recognize the host as foreign and attack the recipient's body cells. "Graft" refers to transplanted, or donated tissue, and "host" refers to the tissues of the recipient. It is a common complication after allogeneic hematopoietic stem cell transplant (HCT). GvHD has been classically classified based on the timing of presentation into acute and chronic using a cutoff of 100 days post-transplant.

Graft versus host disease Emerging Drugs

• MaaT013: MaaT Pharma
MaaT Pharma is developing MaaT013, which is made up of allogeneic, full-ecosystem pooled bio therapeutic intestinal micro biota manufactured in France, per the GMP requirements. It is an off-the-shelf, standardized, pooled-donor, high-richness micro biome bio therapeutic in enema formulation. The product is characterized by a high diversity and consistent richness of microbial species. MaaT013 aims to restore the symbiotic relationship between the patient's functional gut micro biome and their immune system to correct the responsiveness and tolerance of immune functions and thus reduce steroid-resistant, gastrointestinal-predominant aGvHD. In previous studies, MaaT013 showed interesting results; therefore, warranted as salvage therapy in steroid and JAK inhibitors-resistant GI-aGvHD patients.

• MC0518: Medac
Obnitix, also called MC0518, is a new special preparation of mesenchymal stromal cells (MSC) produced with the help of an innovative process by Medac. Obnitix is administered via an infusion. The administration of Obnitix, which uses mononuclear cells from the bone marrow of at least eight donors, activates a suppression of pro-inflammatory messenger substances and T-cell suppression. The new method has made it possible to obtain a uniform and reproducible product with stable batch production. Currently, the drug is in the Phase III stage of its development for the treatment of Graft versus host disease.

• SNDX-6532: Syndax Pharmaceutical
Axatilimab (SNDX-6352) is an investigational high-affinity antibody targeting the colony-stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be a key regulatory pathway involved in the expansion and infiltration of donor-derived macrophages that mediate the disease processes involved in cGvHD. The company believes that CSF-1R blockade with axatilimab (SNDX-6352) may reduce the number of these pro-inflammatory macrophages and play a vital role in treating cGvHD. As of now, an ongoing Phase II (NCT04710576, AGAVE-201) study will assess the efficacy, protection, and tolerability of axatilimab, a CSF-1R inhibitor, at three different dose levels in patients with persistent or refractory active cGvHD who have undergone at least two prior lines of systemic therapy due to disease progression, intolerance, or toxicity.

• Neihulizumab: AltruBio
Neihulizumab/ALTB-168 is a humanized therapeutic antibody with a unique mechanism of action, preferentially inducing apoptosis of late-stage activated T cells. This novel activated-T cell apoptosis-inducing antibody effectively eliminates chronic pathogenic T cells while fully maintaining host defense, leading to durable clinical efficacy without increasing the risk of infection or cancer.These two characteristics, which have been well demonstrated in our proof of concept clinical studies, offer a sustainable competitive advantage over existing therapies. Currently, the drug is in the Phase I stage of its development for the treatment of Graft versus host disease.

Learn more about Graft Versus Host Disease in clinical trials @ Graft Versus Host Disease Drugs- https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Graft Versus Host Disease Therapeutics Assessment
There are approx. 60+ key companies which are developing the Graft versus host disease (GVHD) therapies. The GVHD companies which have their drug candidates in the most advanced stage, i.e Phase III include MaaT Pharma

DelveInsight's Graft versus host disease pipeline report covers around 65+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Discover more about Graft Versus Host Disease in development @ Graft Versus Host Disease Clinical Trials- https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Graft Versus Host Disease Companies
AltruBio, Syndax Pharmaceutical, MaaT Pharma, Medac, CSL Behring, Takeda, Oncoimmue, ElsaLys Biotech, Xenikos, Incyte Corporation, Jazz Pharmaceutials, Kadmon Corporation, Regimmune Corporation, Medsenic, AstraZeneca, Biogen, Pfizer, Equillium, GlaxoSmithKline, Amgen, CTI BioPharma, Bristol-Myers Squibb, Synthetic Biologics, Evive Biotech, Orca Bio, Novartis, Roche, Millennium, and others.

GVHD pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Graft versus host disease Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

To know more about Graft Versus Host Disease, visit @ Graft Versus Host Disease Segmentation- https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Graft versus host disease Pipeline Report
• Coverage- Global
• Graft versus host disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Graft versus host disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Graft versus host disease Companies- AltruBio, Syndax Pharmaceutical, MaaT Pharma, Medac, CSL Behring, Takeda, Oncoimmue, ElsaLys Biotech, Xenikos, Incyte Corporation, Jazz Pharmaceutials, Kadmon Corporation, Regimmune Corporation, Medsenic, AstraZeneca, Biogen, Pfizer, Equillium, GlaxoSmithKline, Amgen, CTI BioPharma, Bristol-Myers Squibb, Synthetic Biologics, Evive Biotech, Orca Bio, Novartis, Roche, Millennium, and others.
• Graft versus host disease Pipeline Therapies- Ibrutinib, Prednisone, ruxolitinib, Axatilimab, GDC-8264, Ruxolitinib, Defibrotide, and others.

For further information on the Graft Versus Host Disease Pipeline Therapeutics, reach out @ Graft Versus Host Disease Products Development- https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Graft versus host disease Executive Summary
3. Graft versus host disease: Overview
4. Graft versus host disease Pipeline Therapeutics
5. Graft versus host disease Therapeutic Assessment
6. Graft versus host disease- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. MaaT013: MaaT Pharma
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. SNDX-6532: Syndax Pharmaceutical
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Neihulizumab: AltruBio
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Graft versus host disease Key Companies
21. Graft versus host disease Key Products
22. Graft versus host disease- Unmet Needs
23. Graft versus host disease- Market Drivers and Barriers
24. Graft versus host disease- Future Perspectives and Conclusion
25. Graft versus host disease Analyst Views
26. Graft versus host disease Key Companies
27. Appendix

List of Top Selling Market Research Reports in 2024

carcinoid syndrome market- https://www.delveinsight.com/report-store/carcinoid-tumor-market
fabry disease market- https://www.delveinsight.com/report-store/fabry-disease-market
gene therapy in cns disorder market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market
lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
surgical lasers market- https://www.delveinsight.com/report-store/surgical-lasers-market
transcatheter treatment market - https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market
wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market
intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
scoliosis market - https://www.delveinsight.com/report-store/scoliosis-market
stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
vitreoretinal surgery devices market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
diabetic wound market- https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
lymphoedema market- https://www.delveinsight.com/report-store/lymphedema-market
nk cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
sglt2 inhibitors market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market
mouth neoplasms market- https://www.delveinsight.com/sample-request/mouth-neoplasms-market
somatotropin deficiency market - https://www.delveinsight.com/report-store/somatotropin-deficiency-market
meningococcal meningitis market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market
seltorexant drug market- https://www.delveinsight.com/report-store/major-depressive-disorder-market
surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
antibody drug conjugate market - https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
skin neoplasm market- https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market
asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.